-
Joe Cohen, co-inventor of malarial vaccine and GlaxoSmithKline researcher addresses a press conference on November 3, 2009 on the sidelines of the ongoing Multilateral Interventions on Malaria, MIM-PAMC conference in the Kenyan capital, Nairobi. The... View Photo »
-
Picture of two flasks allowing to blend several doses, an adjuvant and a antigen, of Pandemrix A(H1N1) vaccine ( from Glaxo Smith Kline -GSK- laboratory), taken at Pellegrin hospital on October 28, 2009 in Bordeaux, southwestern France. As France... View Photo »
-
From the Web
-
(Adds closing share prices in fifth and 11th paragraphs.) March 18 (Bloomberg) -- Novartis AG returned U.S. development rights to a generic version of an asthma drug to U.K. partner Vectura Group Plc, potentially easing the threat to GlaxoSmithKline P Full Article at Business Week
-
A Duke University graduate, Stiefel wanted his windfall to better society. Like many modern philanthropists, such as Bill and Melinda Gates or Warren Buffett, Stiefel is not motivated by religious zeal. In fact, Stiefel has become one of the country's... Full Article at RichardDawkins.net
-
That move gives Glaxo one less problem to worry about. GSK chief Andrew Witty has been pooh-poohing the potential of generic rivals to that best-selling lung drug, which accounted for $7.6 billion in 2009 sales. The inhaled drug isn't easy to make,... Full Article at FiercePharma
-
RALEIGH, Mar 18, 2010 (The News and Observer - McClatchy-Tribune Information Services via COMTEX) -- To see more of The News & Observer, or to subscribe to the newspaper, go to http://www.newsobserver.com. Copyright (c) 2010, The News and Observer, Full Article at Trading Markets
-
LONDON (MarketWatch) -- Concerns about competition for a key GlaxoSmithKline asthma drug were alleviated on Thursday, after the transfer of the U.S. development rights of a potential generic rival product. GlaxoSmithKline /quotes/comstock/23s!a:gsk (UK Full Article at MarketWatch
-
Emisphere Technologies and Alchemia to Research an Oral Formulation of Fondaparinux with Eligen® Technology
Freshnews.comCEDAR KNOLLS, N.J. & BRISBANE, Australia -- (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) and Alchemia Ltd. (ASX:ACL) today announced that they are joining efforts to develop an oral formulation of the anti-coagulant drug fondaparinux wit Full Article at Freshnews.com
-
GlaxoSmithKline Up as Novartis Corporation Drops Generic Advair in U.S.; Hands Back U.S. Rights to VR315 to Vectura Limited
BiospaceGlaxoSmithKline (GSK) Up as Novartis Corporation (NVS) Drops Generic Advair in U.S. ; Novartis Hands Back U.S. Rights to VR315 to Vectura Limited 3/18/2010 Reuters -- Novartis has handed back U.S. rights to a drug widely be Full Article at Biospace
-
In the doldrums too were banks as investors took a breather following a strong run of gains in the sector. Royal Bank of Scotland, slipped1.6pc, Lloyds Banking Group fell 1.2pc and HSBC dropped 1pc in morning trading. Following yesterday’s highs, inves Full Article at The Telegraph
-
LONDON (MarketWatch) -- European shares edged higher on Thursday afternoon to build on annual highs. Healthcare stocks were advancing, with GlaxoSmithKline /quotes/comstock/23s!a:gsk (UK:GSK 1,260, +35.00, +2.86%) shares up 2.8% after a generic threa Full Article at Wall Street Journal
-
LONDON (MarketWatch) -- GlaxoSmithKline shares climbed on Thursday amid signs that investors could be reassessing the prospects for a U.S. generic launch of one of its key asthma drugs. Democrats may be close to pushing through their health bill, even Full Article at MarketWatch
